- Markets
- Healthcare
- NECLIFE
NECLIFE
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Nectar Lifesciences falls after European agencies flag concerns at facility
** Nectar Lifesciences NECT.NS drops exchange-allowed maximum of 5% to 26.37 rupees
** European Directorate for Quality of Medicines & HealthCare and Spanish Agency of Medicines and Medical Devices issue seven observations to co's API manufacturing facility in Punjab's Mohali
** Co says it will prepare corrective action and preventive action report to address observations
** NECT falls 32.4% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Nectar Lifesciences NECT.NS drops exchange-allowed maximum of 5% to 26.37 rupees
** European Directorate for Quality of Medicines & HealthCare and Spanish Agency of Medicines and Medical Devices issue seven observations to co's API manufacturing facility in Punjab's Mohali
** Co says it will prepare corrective action and preventive action report to address observations
** NECT falls 32.4% YTD
(Reporting by Vijay Malkar)
(([email protected];))
Nectar Lifesciences Says API Manufacturing Facility, Punjab Undergone Joint Inspection By EDQM, AEMPS
March 10 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
API MANUFACTURING FACILITY, PUNJAB UNDERGONE JOINT INSPECTION BY EDQM, AEMPS
FOLLOWING INSPECTION, SEVEN OBSERVATIONS INCLUDING FOUR CRITICAL, WERE NOTED.
EUROPEAN REGULATOR WILL CONDUCT A RE-INSPECTION OF FACILITY
Further company coverage: NECT.NS
(([email protected];;))
March 10 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
API MANUFACTURING FACILITY, PUNJAB UNDERGONE JOINT INSPECTION BY EDQM, AEMPS
FOLLOWING INSPECTION, SEVEN OBSERVATIONS INCLUDING FOUR CRITICAL, WERE NOTED.
EUROPEAN REGULATOR WILL CONDUCT A RE-INSPECTION OF FACILITY
Further company coverage: NECT.NS
(([email protected];;))
Nectar Lifesciences Receives Tax Relief Of 35.8 Mln Rupees
Jan 20 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
RECEIVES TAX RELIEF OF 35.8 MILLION RUPEES
Source text: ID:nBSEbbd3nF
Further company coverage: NECT.NS
(([email protected];;))
Jan 20 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
RECEIVES TAX RELIEF OF 35.8 MILLION RUPEES
Source text: ID:nBSEbbd3nF
Further company coverage: NECT.NS
(([email protected];;))
Nectar Lifesciences Says Investment Agreement With Isengard Direct PE LLC Stands Terminated
Dec 13 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
ISENGARD DIRECT PE LLC, ITS ASSOCIATES HAVE SOLD ALL OF THEIR SHARES
INVESTMENT AGREEMENT WITH ISENGARD DIRECT PE LLC STANDS TERMINATED
Source text: ID:nNSE6xx3JW
Further company coverage: NECT.NS
(([email protected];;))
Dec 13 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
ISENGARD DIRECT PE LLC, ITS ASSOCIATES HAVE SOLD ALL OF THEIR SHARES
INVESTMENT AGREEMENT WITH ISENGARD DIRECT PE LLC STANDS TERMINATED
Source text: ID:nNSE6xx3JW
Further company coverage: NECT.NS
(([email protected];;))
Nectar Lifesciences Sept-Quarter Consol Profit From Continuing Operations 56 Million Rupees
Nov 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 56 MILLION RUPEES
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.28 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
Nov 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 56 MILLION RUPEES
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.28 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
Nectar Lifesciences June-Quarter Consol Profit From Cont Ops 29.7 Million Rupees
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 29.7 MILLION RUPEES
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.59 BILLION RUPEES
Source text for Eikon: ID:nBSEc02H56
Further company coverage: NECT.NS
(([email protected];))
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 29.7 MILLION RUPEES
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.59 BILLION RUPEES
Source text for Eikon: ID:nBSEc02H56
Further company coverage: NECT.NS
(([email protected];))
Nectar Lifesciences March-Quarter Consol Profit From Continuing Operations Falls
May 15 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 5.9 MILLION RUPEES VERSUS PROFIT 36.8 MILLION RUPEES
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES VERSUS 3.88 BILLION RUPEES
Source text for Eikon: ID:nBSE392nGx
Further company coverage: NECT.NS
(([email protected];;))
May 15 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 5.9 MILLION RUPEES VERSUS PROFIT 36.8 MILLION RUPEES
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES VERSUS 3.88 BILLION RUPEES
Source text for Eikon: ID:nBSE392nGx
Further company coverage: NECT.NS
(([email protected];;))
Nectar Lifesciences Reports Profit For Dec-Qtr
Feb 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES DEC-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 15.7 MILLION RUPEES VERSUS LOSS 92.9 MILLION RUPEES
NECTAR LIFESCIENCES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.52 BILLION RUPEES VERSUS 3.44 BILLION RUPEES
Source text for Eikon: ID:nBSE6MsHdt
Further company coverage: NECT.NS
(([email protected];;))
Feb 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES DEC-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 15.7 MILLION RUPEES VERSUS LOSS 92.9 MILLION RUPEES
NECTAR LIFESCIENCES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.52 BILLION RUPEES VERSUS 3.44 BILLION RUPEES
Source text for Eikon: ID:nBSE6MsHdt
Further company coverage: NECT.NS
(([email protected];;))
India's Nectar Lifesciences June-Quarter Consol Profit From Cont Ops Falls
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
INDIA'S NECTAR LIFESCIENCES JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 18.2 MILLION RUPEES VERSUS PROFIT 39 MILLION RUPEES
NECTAR LIFESCIENCES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.94 BILLION RUPEES VERSUS 4.03 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
INDIA'S NECTAR LIFESCIENCES JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 18.2 MILLION RUPEES VERSUS PROFIT 39 MILLION RUPEES
NECTAR LIFESCIENCES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.94 BILLION RUPEES VERSUS 4.03 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
India's Nectar Life Sciences March-Quarter Consol Profit From Continuing Operations Falls
May 26 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 36.8 MILLION RUPEES VERSUS 116.6 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.88 BILLION RUPEES VERSUS 4.76 BILLION RUPEES
Source text for Eikon: ID:nBSE1Vq5DQ
Further company coverage: NECT.NS
(([email protected];))
May 26 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 36.8 MILLION RUPEES VERSUS 116.6 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.88 BILLION RUPEES VERSUS 4.76 BILLION RUPEES
Source text for Eikon: ID:nBSE1Vq5DQ
Further company coverage: NECT.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Nectar Lifesciences do?
Nectar Lifesciences is a key player in the Indian Pharmaceutical Industry, specializing in Global Cephalosporins within Anti Infective Therapeutic segment. The company is expanding globally by entering regulated markets like US and European Union.
Who are the competitors of Nectar Lifesciences?
Nectar Lifesciences major competitors are SMS Lifesciences, NGL Fine-Chem, Everest Organics, Bal Pharma, Tyche Inds, Smruthi Organics, Mangalam Drugs&Org.. Market Cap of Nectar Lifesciences is ₹521 Crs. While the median market cap of its peers are ₹174 Crs.
Is Nectar Lifesciences financially stable compared to its competitors?
Nectar Lifesciences seems to be less financially stable compared to its competitors. Altman Z score of Nectar Lifesciences is 1.99 and is ranked 8 out of its 8 competitors.
Does Nectar Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Nectar Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Nectar Lifesciences allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable
How strong is Nectar Lifesciences balance sheet?
Balance sheet of Nectar Lifesciences is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Nectar Lifesciences improving?
Yes, profit is increasing. The profit of Nectar Lifesciences is ₹17 Crs for TTM, ₹5 Crs for Mar 2024 and -₹24.18 Crs for Mar 2023.
Is the debt of Nectar Lifesciences increasing or decreasing?
Yes, The debt of Nectar Lifesciences is increasing. Latest debt of Nectar Lifesciences is ₹611 Crs as of Sep-24. This is greater than Mar-24 when it was ₹598 Crs.
Is Nectar Lifesciences stock expensive?
Nectar Lifesciences is not expensive. Latest PE of Nectar Lifesciences is 30.67, while 3 year average PE is 38.95. Also latest EV/EBITDA of Nectar Lifesciences is 6.42 while 3yr average is 12.41.
Has the share price of Nectar Lifesciences grown faster than its competition?
Nectar Lifesciences has given lower returns compared to its competitors. Nectar Lifesciences has grown at ~-2.51% over the last 7yrs while peers have grown at a median rate of 12.26%
Is the promoter bullish about Nectar Lifesciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Nectar Lifesciences is 44.53% and last quarter promoter holding is 44.53%.
Are mutual funds buying/selling Nectar Lifesciences?
There is Insufficient data to gauge this.